KT-621 vs PF-08049820

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: STAT6 · full Atopic Dermatitis pipeline

KT-621

Developed by Kymera Therapeutics

Phase 2 in Atopic Dermatitissmall molecule
Weak signal

NCT06945458 · Phase 1 · completed

All 22 participants received KT-621 openly with no control group and no blinding, so there is no way to separate the drug's effect from natural changes over time. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2027 · NCT07217015 (registry estimate)

Reported efficacy

Incidence of adverse events (AEs) (From enrollment through the safety follow-up visit on Day 43); Incidence of treatment-emergent potentially clinically-significant abnormalities in electrocardiogram (ECG) results, vital signs, or laboratory test results from the serum chemistry, hematology (with differential), chemistry, or coagulation panels. (From enrollment through the safety follow-up visit on Day 43): After 28 days of once-daily oral dosing, KT-621 produced an overall mean 63% reduction in EASI and deep STAT6 degradation across both the 100 mg and 200 mg dose groups, with median reductions of 94% in skin and 98% in blood.

Result source: NCT06945458

PF-08049820

Developed by Pfizer

Phase 2 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2028 · NCT07216027 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointKT-621PF-08049820
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change—Not reported—Not reported

EASI-75

KT-621
—Not reported
PF-08049820
—Not reported

IGA 0/1 with 2-point improvement

KT-621
—Not reported
PF-08049820
—Not reported

EASI-90

KT-621
—Not reported
PF-08049820
—Not reported

EASI, % change

KT-621
—Not reported
PF-08049820
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

KT-621: no structured comparison results are available for Atopic Dermatitis.

PF-08049820: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: KT-621's landscape · PF-08049820's landscape